Dec. 2025 – New US patent
River Stone Bio has announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. . Dec. 2025 - New US patent further strengthens River Stone IP . This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection on its unique approach to bioconversion across a range of products. .River RiverStone Biotech - Dec. 2025...
Nov. 2025 – Production of nororipavine
Yeast based N-demethylation for the production of nororipavine in fed-batch or continuous cultivation . In a groundbreaking paper published in Bioresource Technology researchers of University of Melbourne and River Stone it is shown that optimized insect-derived N-demethylases of cytochrome P450 origin can efficiently convert the natural opioid oripavine to the much sought after chemical intermediate nororipavine. With the opioid epidemic ravishing the world cheaper drugs for countering overdose deaths and for treating addiction, access to an affordable supply of the ideal drug precursor nororipavine will be crucial. Using the methodology detailed in the paper, not only can the drugs in question be...
Oct. 2025 – Attending CPHI 2025
River Stone will be attending CPHI in Frankfurt next week - october 2025 . RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes. In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world. River Stone works with a small number of global providers to establish a virtual cross-functional operation to enable its API offering and is looking to strengthen its network of potential partners and customers. . . ...
Mar. 2025 – Enzyme Discovery and In Vivo Assessment
Plant-Derived UDP-Glycosyltransferases for Glycosylation-Mediated Detoxification of Deoxynivalenol: Enzyme Discovery, Characterization, and In Vivo Resistance Assessment . March 2025, Copenhagen - In a paper published in Toxins, DTU (Danish Technical University) and River Stone researchers used River Stone’s 380-member large UGT (UDP-glucose dependent glycosyltransferases) library (Gly-it.com) to identify 8 novel UGTs that could efficiently glycosylate the harmful toxin deoxynivalenol (DON). DON is found in, e.g., Rice, maize, wheat, and barley infected with the plant pathogenic fungus Fusarium graminearum. DON also being toxic to plants these respond by glycosylating the molecule, thereby achieving at least part detoxification. As it is crucial to avoid contamination...
Jul. 2024 – Glycosylation of aloesone
Enzymatic glycosylation of aloesone performed by plant UDP-dependent glycosyltransferases . In a paper published in Glycobiology, researchers of the Danish Technical University (DTU) and River Stone demonstrates that a high number of natural UGTs (UDP-glucose dependent glycosyltransferases) are able to glycosylate the plant molecule aloesone. Aloesone and its derivatives are highly used in cosmetics, and therefore the findings from this work may be very important for this field to progress. For this collaborative program River Stone supplied its 380-member large UGT library, which is commercially available as kit and service, Gly-it.com. https://pmc.ncbi.nlm.nih.gov/articles/PMC11273223/ . ...
Apr. 2022 – Participation DCAT 2022
River Stone Biotech Inc. participates in DCAT 2022 . River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone. The novel patent-protected technology employed will allow reliable supply of these vital APIs at much superior value – both economically and environmentally – to those available in the market today. The technology employs a combination of state-of-the-art synthetic biology followed by other more traditional production methods; this novel...
Nov. 2021 – $6.8M Series B Financing
River Stone Biotech Inc. Announces $6.8M Series B Financing . Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects To Treat Opiate Use Disorder and Opiate Overdose. – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing. Led by an individual specialty healthcare investor, the financing included new investments from 5 private investors along with further participation from existing investor, Dick Cashin. In conjunction with the financing, James (Jeb) Besser, has...